Oncology Investigator Studies Program (MISP)
To advance science and improve patient care by supporting, through the provision of drug and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.
Due to the recent partnership with Eisai, MSD will now be jointly evaluating proposals with lenvatinib. Proposals involving lenvatinib as monotherapy or in combination with drugs
other than pembrolizumab should be submitted through the portal on the Eisai website
Proposals involving the combination of lenvatinib and pembrolizumab should be submitted to MSD.